The Irrelevance of Social Media for Pharma Marketing

The pharmaceutical industry has often been criticized for being behind the "digital curve," meaning that it lacks the expertise to fully take advantage of the Internet and social media to improve marketing and communications.

Back in 2013, I suggested that pharma was on the "Slope of Enlightenment" of the "digital" hype curve (here).

Since then, the FDA has come out with some social media guidelines (read, for example, FDA Sets Up a Roadblock for Branded Rx Promotional Tweets and Drug Industry Rips Into FDA Over Social Media Guidelines) and I sense that pharma has moved along the curve, but the curve itself - which I am now calling the Social Media (SM) Hype Curve - has changed and it looks something like this:

Click on image for an enlarged view.

What do I mean by "Slow Slide Into Irrelevance?"

Read more »